This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (308)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Neurology  • Alzheimer Disease  • Randomized Controlled Trial  • Alert me on articles by topic

A Randomized Controlled Trial

Pierre N. Tariot, MD; Martin R. Farlow, MD; George T. Grossberg, MD; Stephen M. Graham, PhD; Scott McDonald, PhD; Ivan Gergel, MD; for the Memantine Study Group

JAMA. 2004;291:317-324.

Context  Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. Controlled trials have demonstrated the safety and efficacy of memantine monotherapy for patients with moderate to severe Alzheimer disease (AD) but no controlled trials of memantine in patients receiving a cholinesterase inhibitor have been performed.

Objective  To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatment with donepezil.

Design, Setting, and Participants  A randomized, double-blind, placebo-controlled clinical trial of 404 patients with moderate to severe AD and Mini-Mental State Examination scores of 5 to 14, who received stable doses of donepezil, conducted at 37 US sites between June 11, 2001, and June 3, 2002. A total of 322 patients (80%) completed the trial.

Interventions  Participants were randomized to receive memantine (starting dose 5 mg/d, increased to 20 mg/d, n = 203) or placebo (n = 201) for 24 weeks.

Main Outcome Measures  Change from baseline on the Severe Impairment Battery (SIB), a measure of cognition, and on a modified 19-item AD Cooperative Study–Activities of Daily Living Inventory (ADCS-ADL₁₉). Secondary outcomes included a Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus), the Neuropsychiatric Inventory, and the Behavioral Rating Scale for Geriatric Patients (BGP Care Dependency Subscale).

Results  The change in total mean (SE) scores favored memantine vs placebo treatment for SIB (possible score range, 0-100), 0.9 (0.67) vs –2.5 (0.69), respectively (P<.001); ADCS-ADL₁₉ (possible score range, 0-54), –2.0 (0.50) vs –3.4 (0.51), respectively (P = .03); and the CIBIC-Plus (possible score range, 1-7), 4.41 (0.074) vs 4.66 (0.075), respectively (P = .03). All other secondary measures showed significant benefits of memantine treatment. Treatment discontinuations because of adverse events for memantine vs placebo were 15 (7.4%) vs 25 (12.4%), respectively.

Conclusions  In patients with moderate to severe AD receiving stable doses of donepezil, memantine resulted in significantly better outcomes than placebo on measures of cognition, activities of daily living, global outcome, and behavior and was well tolerated. These results, together with previous studies, suggest that memantine represents a new approach for the treatment of patients with moderate to severe AD.

Author Affiliations: Departments of Psychiatry, Medicine, Neurology, and the Center for Aging and Developmental Biology, University of Rochester Medical Center, Monroe Community Hospital, Rochester, NY (Dr Tariot); Department of Neurology, Indiana University School of Medicine, Indianapolis (Dr Farlow); Department of Geriatric Psychiatry, St Louis University School of Medicine, St Louis, Mo (Dr Grossberg); Forest Laboratories Inc, Jersey City, NJ (Drs Graham, McDonald, and Gergel).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dementia of the Alzheimer Type
Jalbert et al.
Epidemiol Rev 2008;0:mxn008v1-mxn008.
ABSTRACT | FULL TEXT  

Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians
Qaseem et al.
ANN INTERN MED 2008;148:370-378.
ABSTRACT | FULL TEXT  

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
Raina et al.
ANN INTERN MED 2008;148:379-397.
ABSTRACT | FULL TEXT  

Efficacy of Memantine on Behavioral and Psychological Symptoms Related to Dementia: A Systematic Meta-Analysis
Maidment et al.
The Annals of Pharmacotherapy 2008;42:32-38.
ABSTRACT | FULL TEXT  

Alzheimer's Disease: Will Advances Made in the Past Turn the Tide?
Semla
The Annals of Pharmacotherapy 2007;41:1494-1496.
FULL TEXT  

Dementia and Comorbidities: An Overview of Diagnosis and Management
Swanson and Carnahan
Journal of Pharmacy Practice 2007;20:296-317.
ABSTRACT  

Does This Patient Have Dementia?
Holsinger et al.
JAMA 2007;297:2391-2404.
ABSTRACT | FULL TEXT  

Should One Use Medications in Combination With Cognitive Training? If So, Which Ones?
Yesavage et al.
J. Gerontol. B Psychol. Sci. Soc. Sci. 2007;62:11-18.
ABSTRACT | FULL TEXT  

Different conclusions about memantine
Lexchin
cfp 2007;53:403-404.
FULL TEXT  

Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia
Blaszczyk and Mathys
Journal of Pharmacy Practice 2007;20:13-28.
ABSTRACT  

Maladie d'Alzheimer
Massoud
cfp 2007;53:50-54.
ABSTRACT | FULL TEXT  

Evidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's Disease
Chiappelli et al.
Evid Based Complement Alternat Med 2006;3:411-424.
ABSTRACT | FULL TEXT  

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Burns and O'Brien
J Psychopharmacol 2006;20:732-755.
ABSTRACT  

Therapeutic approaches to Alzheimer's disease
Klafki et al.
Brain 2006;129:2840-2855.
ABSTRACT | FULL TEXT  

A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease
Tarraga et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:1116-1121.
ABSTRACT | FULL TEXT  

Acceleration of Amyloid beta-Peptide Aggregation by Physiological Concentrations of Calcium
Isaacs et al.
J. Biol. Chem. 2006;281:27916-27923.
ABSTRACT | FULL TEXT  

Use of memantine to treat Alzheimer's disease.
Gauthier et al.
CMAJ 2006;175:501-502.
FULL TEXT  

Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial
Peskind et al.
AJGP 2006;14:704-715.
ABSTRACT | FULL TEXT  

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Cummings et al.
Neurology 2006;67:57-63.
ABSTRACT | FULL TEXT  

Neuropsychiatric Features of Dementia: What is the Big Picture?
Tariot
AJGP 2006;14:557-560.
FULL TEXT  

Position Statement of the American Association for Geriatric Psychiatry Regarding Principles of Care for Patients With Dementia Resulting From Alzheimer Disease
Lyketsos et al.
AJGP 2006;14:561-573.
FULL TEXT  

Effects of Donepezil on Neuropsychiatric Symptoms in Patients With Dementia and Severe Behavioral Disorders
Cummings et al.
AJGP 2006;14:605-612.
ABSTRACT | FULL TEXT  

Rationale for Combination Therapy With Galantamine and Memantine in Alzheimer's Disease
Grossberg et al.
J Clin Pharmacol 2006;46:17S-26S.
ABSTRACT | FULL TEXT  

Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial.
Callahan et al.
JAMA 2006;295:2148-2157.
ABSTRACT | FULL TEXT  

The Importance of Cognition in the Conceptualization of both Dementia and Severe Mental Illness in Older People.
Twamley and Harvey
AJGP 2006;14:387-390.
FULL TEXT  

A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.
van Dyck et al.
AJGP 2006;14:428-437.
ABSTRACT | FULL TEXT  

Low Doses of Memantine Disrupt Memory in Adult Rats
Creeley et al.
J. Neurosci. 2006;26:3923-3932.
ABSTRACT | FULL TEXT  

Prediction of Psychosis Onset in Alzheimer Disease: The Role of Cognitive Impairment, Depressive Symptoms, and Further Evidence for Psychosis Subtypes
Wilkosz et al.
AJGP 2006;14:352-360.
ABSTRACT | FULL TEXT  

Managing patients with Alzheimer's disease
Corey-Bloom et al.
PN 2006;6:78-89.
FULL TEXT  

Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics
Peters et al.
Neurology 2006;66:523-528.
ABSTRACT | FULL TEXT  

A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Reisberg et al.
Arch Neurol 2006;63:49-54.
ABSTRACT | FULL TEXT  

Treatment of dementia
Overshott and Burns
J. Neurol. Neurosurg. Psychiatry 2005;76:v53-v59.
FULL TEXT  

Development of a Short Form of the Severe Impairment Battery
Saxton et al.
AJGP 2005;13:999-1005.
ABSTRACT | FULL TEXT  

Translational Research on the Way to Effective Therapy for Alzheimer Disease
Rosenberg
Arch Gen Psychiatry 2005;62:1186-1192.
ABSTRACT | FULL TEXT  

Moderate to severe Alzheimer disease: Definition and clinical relevance
Farlow
Neurology 2005;65:S1-S4.
FULL TEXT  

Neuroanatomy/pathology and the interplay of neurotransmitters in moderate to severe Alzheimer disease
Francis
Neurology 2005;65:S5-S9.
FULL TEXT  

Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer disease
Cummings
Neurology 2005;65:S18-S24.
FULL TEXT  

The search for disease modification in moderate to severe Alzheimer disease: A critical review of current evidence
Farlow
Neurology 2005;65:S25-S30.
FULL TEXT  

Pharmacological Implications of Two Distinct Mechanisms of Interaction of Memantine with N-Methyl-D-aspartate-Gated Channels
Chen and Lipton
J. Pharmacol. Exp. Ther. 2005;314:961-971.
ABSTRACT | FULL TEXT  

Antipsychotic Dose-Sparing Effect with Addition of Memantine
Sleeper
The Annals of Pharmacotherapy 2005;39:1573-1576.
ABSTRACT | FULL TEXT  

Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine
Ridha et al.
Neurology 2005;65:481-482.
ABSTRACT | FULL TEXT  

Diagnosis and treatment of Alzheimer's disease
Desai and Grossberg
Neurology 2005;64:S34-S39.
ABSTRACT | FULL TEXT  

{beta}-Amyloid-Stimulated Microglia Induce Neuron Death via Synergistic Stimulation of Tumor Necrosis Factor {alpha} and NMDA Receptors
Floden et al.
J. Neurosci. 2005;25:2566-2575.
ABSTRACT | FULL TEXT  

Memantine: Targeting glutamate excitotoxicity in Alzheimer's disease and other dementias
Molinuevo et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2005;20:77-85.
ABSTRACT  

Cholinesterase Inhibitors in the Treatment of Dementia
Ellis
JAOA: Journal of the American Osteopathic Association 2005;105:145-158.
ABSTRACT | FULL TEXT  

Memory Dysfunction
Budson and Price
NEJM 2005;352:692-699.
FULL TEXT  

Seizures associated with memantine use
Peltz et al.
Am J Health Syst Pharm 2005;62:420-421.
FULL TEXT  

Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink et al.
JAMA 2005;293:596-608.
ABSTRACT | FULL TEXT  

Mixed Dementia: Emerging Concepts and Therapeutic Implications
Langa et al.
JAMA 2004;292:2901-2908.
ABSTRACT | FULL TEXT  

Memantine Improves Spatial Learning in a Transgenic Mouse Model of Alzheimer's Disease
Minkeviciene et al.
J. Pharmacol. Exp. Ther. 2004;311:677-682.
ABSTRACT | FULL TEXT  

Polypharmacy: A New Paradigm for Quality Drug Therapy in the Elderly?
Gurwitz
Arch Intern Med 2004;164:1957-1959.
FULL TEXT  

A Step Back in Time: Is There a Place for Older Drugs in the Treatment of Dementia?
Belgeri and Morley
J. Gerontol. A Biol. Sci. Med. Sci. 2004;59:M1025-M1028.
FULL TEXT  

ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB
Evid. Based Med. 2004;9:131-131.
FULL TEXT  

Zero Tolerance for Physical Restraints: Difficult But Not Impossible
Flaherty
J. Gerontol. A Biol. Sci. Med. Sci. 2004;59:M919-M920.
FULL TEXT  

Mechanism of Action of Galantamine on N-Methyl-D-Aspartate Receptors in Rat Cortical Neurons
Moriguchi et al.
J. Pharmacol. Exp. Ther. 2004;310:933-942.
ABSTRACT | FULL TEXT  

Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil
Periclou et al.
The Annals of Pharmacotherapy 2004;38:1389-1394.
ABSTRACT | FULL TEXT  

Memantine Protects Hippocampal Neuronal Function in Murine Human Immunodeficiency Virus Type 1 Encephalitis
Anderson et al.
J. Neurosci. 2004;24:7194-7198.
ABSTRACT | FULL TEXT  

Memantine plus donepezil improves physical and mental health in people with Alzheimer's disease
McShane
Evid. Based Ment. Health 2004;7:76-76.
FULL TEXT  

Alzheimer's Disease
Cummings
NEJM 2004;351:56-67.
FULL TEXT  

Memantine: A New Approach to Treatment of Moderate to Severe Alzheimer Disease
JWatch Neurology 2004;2004:1-1.
FULL TEXT  

Other articles noted
Evid. Based Med. 2004;9:95-96.
FULL TEXT  

Memantine for Patients With Alzheimer Disease
Finucane
JAMA 2004;291:1695-1695.
FULL TEXT  

An Evidence-Based Approach to the Management of Agitation in the Geriatric Patient
Cheong
Focus 2004;2:197-205.
FULL TEXT  

Combining Drugs in the Treatment of Alzheimer Disease
JWatch Psychiatry 2004;2004:1-1.
FULL TEXT  

Adding Memantine to Donepezil Is Effective for Alzheimer Disease
JWatch General 2004;2004:4-4.
FULL TEXT